Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year

JAMA - Journal of the American Medical Association

Volumn 317, Issue 10, 2017, Pages 1075-1077

  Winslow, Rebecca L ^a   Milligan, Iain D ^a   Voysey, Merryn ^a   Luhn, Kerstin ^b   Shukarev, Georgi ^b   Douoguih, Macaya ^b   Snape, Matthew D ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Janssen   (Netherlands)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS TYPE 26 VECTOR VACCINE; CYTOKINE; EBOLA VACCINE; IMMUNOGLOBULIN G; MODIFIED VACCINIA VIRUS ANKARA VECTOR VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VIRUS VECTOR; GLYCOPROTEIN; VIRAL PROTEIN; VIRUS ANTIBODY;

ADENOVIRIDAE; ADENOVIRUS TYPE 26; ADULT; ADVERSE OUTCOME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTIOUS DOSE; LETTER; MALE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VACCINIA VIRUS; VIRUS PARTICLE; BLOOD; CLINICAL TRIAL; HEMORRHAGIC FEVER, EBOLA; IMMUNIZATION; IMMUNOLOGY; SECONDARY IMMUNIZATION; SINGLE BLIND PROCEDURE; T LYMPHOCYTE; TIME FACTOR;

ADENOVIRIDAE; ADULT; ANTIBODIES, VIRAL; EBOLA VACCINES; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; SINGLE-BLIND METHOD; T-LYMPHOCYTES; TIME FACTORS; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 85015830681     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.20644     Document Type: Letter

References (6)

1. Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored Ebola vaccines. JAMA. 2016;315(15):1610-1623
2. Osterholm M, Moore K, Ostrowsky J, Kimball-Baker K, Farrar J;Wellcome Trust-CIDRAP Ebola Vaccine Team B. The Ebola Vaccine Team B. Lancet Infect Dis. 2016;16(1):e1-e9
3. Deen GF, Knust B, Broutet N, et al. Ebola RNA persistence in semen of Ebola virus disease survivors-preliminary report. N Engl J Med. 2015
4. Christie A, Davies-Wayne GJ, Cordier-Lassalle T, et al. Possible sexual transmission of Ebola virus-Liberia, 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(17):479-481
5. Dye JM, Herbert AS, Kuehne AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA. 2012;109(13):5034-5039
6. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein. Lancet. 2015; 386(9996):857-866